⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21719800 | 0.78 | CA1 (0.34) | — | |
| SCHEMBL31503587 | 0.71 | ALDH1A1 (0.39) | — | |
| SCHEMBL1106086 | 0.69 | KCNH2 (0.33) | — | |
| SCHEMBL1204756 | 0.69 | CA1 (0.32) | — | |
| SCHEMBL12221323 | 0.67 | — | — | |
| SCHEMBL21719642 | 0.67 | — | — | |
| SCHEMBL12221381 | 0.67 | — | — | |
| SCHEMBL1130511 | 0.67 | — | — | |
| SCHEMBL6872093 | 0.64 | — | — | |
| SCHEMBL12221397 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | BRADBURY ROBERT H | 2007-10-04 | — | — | US | disclosed |
| EP-1756088-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005118572-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2005-12-15 | — | — | WO | disclosed |
| US-6617347-B1 | Substituted pyrazoles are treatment of Type II diabetes and obesity. | ELI LILLY AND COMPANY | 2003-09-09 | — | — | US | disclosed |
| EP-1036064-A4 | SELECTIVE BETA 3-ADRENERGIC AGONISTS | LILLY CO ELI (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6232337-B1 | USEFUL IN THE TREATMENT OF TYPE II DIABETES AND OBESITY | ELI LILLY AND COMPANY | 2001-05-15 | — | — | US | disclosed |
| EP-1036064-A1 | SELECTIVE BETA 3-ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2000-09-20 | — | — | EP | disclosed |
| US-6046227-A | USEFUL IN THE TREATMENT OF TYPE II DIABETES AND OBESITY; A SUBSTITUTED PYRAZINE COMPOUND | ELI LILLY AND COMPANY (US) | 2000-04-04 | — | — | US | disclosed |
| WO-1999029673-A1 | SELECTIVE β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 1999-06-17 | — | — | WO | disclosed |
| WO-1999029672-A1 | SELECTIVE β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 1999-06-17 | — | — | WO | disclosed |
| EP-0921120-A1 | Selective beta 3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1999-06-09 | — | — | EP | disclosed |